Q2 STOCKS TO BUY

Proteostasis Stock at Bottom of Nasdaq After Drug Data, Downgrade

Early data for PTI's cystic fibrosis treatment disappointed analysts

Managing Editor
Jun 7, 2018 at 10:16 AM
facebook X logo linkedin


Proteostasis Therapeutics Inc (NASDAQ:PTI) has fallen to the bottom of the Nasdaq this morning, down 35% to trade at $3.19, after early stage data for the company's cystic fibrosis treatment disappointed analysts -- specifically, its inability to improve lung function. In response, RBC downgraded PTI stock to "sector perform" from "outperform," while more than halving its price target to $5 from $11. 

Looking closer at the charts, PTI stock hit an annual high of $8.61 back in March, before gapping lower in the wake of a scathing short seller report. The security spent the next few months churning in the $4.50--$5.50 range. However, the shares are now on track for their biggest single-session loss since October 2016, and their first close below the 200-day moving average since early March. 

There is ample room for additional downgrades and/or price-target cuts to come down the pike, which could provide more headwinds for the equity. The majority of the brokerages covering the security still rate it a "buy" or "strong buy," and its average 12-month price target of $13.75 is now nearly quadruple PTI's current perch. 

A number of short sellers are likely kicking rocks today. Short interest topped out at a record 3.19 million shares in mid-March, but has since dropped 40% to 1.88 million shares. Nevertheless, this still represents a healthy 13% of PTI's total available float. Short sellers are sitting on the bench today, though, with PTI stock currently on the short-sale restricted list.

 
 

“Buy This Stock Now!” - Expert Who Called 11x On TSLA

He called a rare 11x on Tesla…

But now, thanks to Elon & Trump’s new alliance…

He says there’s a new opportunity that could be 1,000x BIGGER than Tesla – and it could completely revolutionize a $23 Trillion market.

It’s trading for less than $5 per share right now…

But it won’t be under the radar for long.

Discover The 1,000x Bigger Elon Opportunity Here

GRAND SLAM COUNTDOWN

 
 

Featured Articles from Trusted Partners:

👀Learn How Dividends Create Passive Income for Life
Receive $200 Off Motley Fool Epic. The Motley Fool Epic $299 discounted offer is based on $499/year list price. Introductory promotion for new members only. Take control of your money and your portfolio with Motley Fool Epic.

💵New Income System Could Pay You $4,243 Monthly
You could collect an average of $4,243 per month starting as early as next week with a new payout system for income investors. New registrations are being accepted for investors who want to be in a position to start with their first payout next week.

🚀Easy 92% Crypto Dividends (No Coins Required)
COIN stock doesn't pay a dividend... But there's actually a new way to collect a massive dividend that's indirectly based on the stock and offers a terrific monthly income (currently yielding nearly 92% on a forward basis).

🤝Free Advisor Match with Wiseradvisor.com
Don't leave your retirement to chance! Get matched with a trusted financial expert for FREE and make the most of your tax refund. Get started now.

⚠️Dennis Quaid's #1 Warning for Americans
Here's the thing: life doesn't come with guarantees. The economy shifts, markets stumble, and years of hard work could slip through your fingers like sand. But it doesn't have to be that way for you. So request a free copy of this Gold & Silver Guide that will arrive right to your doorstep when you act now.

 

 
 

Follow us on X, Follow us on Twitter